Addex Therapeutics vs Ibio
Ibio is the larger business, with $100,000 of revenue in fiscal 2026 against $36,178 for Addex Therapeutics (2.8 times as much). Ibio grew faster (-75.0% against -92.1%). Addex Therapeutics kept more of each dollar of sales as profit: a net margin of -22448.4% against -33044.0%. Addex Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Addex TherapeuticsADXN, 2025 | IbioIBIO, 2026 |
|---|---|---|
| Revenue | $36,178 | $100,000 |
| Revenue growth | -92.1% | -75.0% |
| Net income | −$8.1m | −$33.0m |
| Operating margin | -9390.8% | -35141.0% |
| Net margin | -22448.4% | -33044.0% |
| Return on equity | -97.4% | -65.7% |
| Free cash flow | −$2.6m | −$23.8m |
| Cash | $2.1m | $56.4m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 23 |
| Market value | $3.7m | $45.5m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 4 buys, 0 sales |